CNTX CNTX
Company Profile ↓Company Overview
CNTX (CNTX) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +1.91% |
| 6 Months: | -71.94% |
| 3 Months: | -71.60% |
| 1 Month: | -1.00% |
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)46.67 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 79.4% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | - | - | -651.06K | -840.32K | -5.03M | -1.57M | -3.44M | -4.01M | -4.05M | -6.67M | -5.29M | -6.18M | -3.82M | -3.09M | -18.70M | -5.53M | -9.76M | -10.61M | -9.34M |
| Net Income | 826.48K | 7.48M | -876.24K | -892.05K | -5.03M | -1.44M | -3.44M | -3.99M | -3.85M | -6.31M | -5.01M | -5.87M | -3.67M | -2.25M | -17.46M | -4.58M | -8.83M | -9.69M | -8.68M |
| Diluted EPS | - | - | -2.52 | -2.55 | -14.18 | -4.00 | -0.22 | -0.25 | -0.24 | -0.40 | -0.31 | -0.37 | -0.23 | -0.04 | -0.22 | -0.05 | -0.09 | -0.10 | -0.09 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Income | -2.57M | -10.53M | -15.38M | -25.07M | -29.92M | -39.70M |
| Net Income | 6.64M | -10.46M | -14.84M | -23.96M | -26.73M | -36.12M |
| Diluted EPS | -3.96 | -3.69 | -0.93 | -1.50 | -0.46 | -0.38 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 467.34K | 51.31M | 37.97M | 16.06M | 98.13M | 68.49M |
| Total Equity | -23.96M | -16.92M | 48.27M | 34.76M | 11.87M | 95.27M | 60.47M |
| Cash & Equivalents | - | 290.67K | 49.64M | 35.50M | 14.45M | 94.43M | 66.00M |
| Total Liabilities | - | 9.62M | 3.03M | 3.21M | 4.19M | 2.86M | 8.02M |
| Current Liabilities | - | 9.55M | 3.03M | 3.21M | 4.19M | 2.75M | 8.02M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -1.03M | -8.80M | -13.55M | -21.05M | -14.56M | -26.39M |
| Investing Cash Flow | 0 | -250.00K | -536.84K | 0 | -14.76M | -2.03M |
| Financing Cash Flow | 1.15M | 58.39M | -102.07K | 0 | 109.29M | -15.27K |
| Capital Expenditure | - | -0 | -36.84K | -0 | -7.32K | -33.95K |
| Free Cash Flow | - | -8.80M | -13.59M | -21.05M | -14.56M | -26.42M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - |
| ROE % | -39.3% | -21.7% | -42.7% | -201.9% | -28.1% | -59.7% |
| ROCE % | 28.3% | -21.8% | -44.3% | -211.2% | -31.4% | -65.7% |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CNTX
Context Therapeutics Ends CT-95, Focuses on Two Cancer Programs - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxNLUZQenFpdlBoU3NPNWJ4RjZOUzFQcmxkQlV0TlBTRUh0TklNNV93ZXE1NEFGOGJGbWlYNkdYM0VpZXhvSHVzUHBTMkxEdmMxLVhReUlERl8tZEpfWVVjdnNwdExDbm5QZV83aWtxMHFSQ3hRNUczanI2S3hvVU91RFhDSUd4UzBMMGtObX…
CNTX Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE9QdTJjV0FzYVpPaTZxUE5OSXJFZnZpVFZubEt3TGUweXg5V2pTYWhzM1dUZFR0bm1VY25wMkFnbkZZdldQX2JUQ0lxbHdUYk5yNEloekZ6bE1JdVNiY1JWU21LYWttalI0bkFpNU1fVE5hVlZQX3E5c0ln?oc=5" target="_blank">CNT…
Maxim Says Context Therapeutics (CNTX)’s Share Pullback Is an Overreaction; Remains Bullish - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxOQkhFazJGSkI0Rm5wbmduVE5OOUtWSjM0bVktakFmM3lYZTJzRTh0MkZrVFF6b0pqcktxd1ZkRFZTQW1aMDJoMUtRWS1MN2p5T0xrQXJUbGozWGxaZzBjV2x5RVZSZnc0djZna0RQeFNrN1oyeWlwVHo5c28wUTdScVBEUzltS1lpUjNfcE…
CNTX|Context Therapeutics Inc|Price:0.603|Chg%:+0.003 - TradingKey
<a href="https://news.google.com/rss/articles/CBMiWkFVX3lxTE1uZmJGVkd1R2R5ODFiMDFGWjlMU0pwdUx3YVk0ZzFqNWJGd0V6eGxmd2JWODRvYzNlYkZEYXFFby1zdk83MzRaLXN4OU1rRDZkbzVrTC1SRVJzUQ?oc=5" target="_blank">CNTX|Context Therapeutics Inc|Price:0.603|Chg…
CNTX Hits Worst Day In History After Ovarian Cancer Trial Data — But Analysts See Buying Opportunity In Dip - Stocktwits
<a href="https://news.google.com/rss/articles/CBMi9wFBVV95cUxOZE1xUmI1N0ZzbVBpOHhGTm5GaG16a3g3YjFpOUlYV2JnNmJyblVfRS1VZ0FoeEF3R0xpc2hiZjU0ejRWSHJGSk9aN3A2X0dKeTl2d3BfS0p3d016N2k5a3pvTUVjYjM1anlSbV8zbFhJUTNJdzVwd2VBYTdySU9wR1FqWkhXZDNqMHRtb0…
Context Therapeutics (NASDAQ: CNTX) faces Nasdaq minimum bid-price deficiency risk - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxOX2FFNXJLa2dPSXFWa2hNSndhdl9TU3paY09VOUhZQjFmVDByRTllcktsaURpbk5SQjlGU1pZaUQ4aVFyWV9Ba0E1aUZUa2VTSVFrbVVhNUpPV0pSMTNHdldzdzhXeDNrZmV3b1R0a20tbWxiSGdodXFlUldzblBDX2hfMXFfZHVKNEJzRD…
CNTX — Frequently Asked Questions
What is the current share price of CNTX?
As of 2026-08-05 17:25 PDT, CNTX trades at $0.69 on NASDAQ/NYSE. Its 52-week range is $0.55 to $3.36.
What is the P/E ratio of CNTX?
CNTX trades at a trailing price-to-earnings (P/E) ratio of -1.82.
What is the return on equity (ROE) of CNTX?
CNTX has a return on equity (ROE) of -59.73%. Its return on capital employed (ROCE) is -65.65%.
Is CNTX a good stock to buy?
This page provides a data-driven analysis of CNTX, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.